Washington—The checkpoint inhibitor avelumab was associated with a rate of survival in patients with metastatic Merkel cell carcinoma (mMCC) not seen with traditional therapies, according to the results of a Phase II trial presented just days after the drug received FDA approval for the indication. At one year of follow-up, 52% of mMCC patients treated with avelumab were still alive.